Paper Details

  1. Home
  2. Paper Details

Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers.

Author: BarlesiFabrice, BauerTodd M, BroseMarcia, BurkardMark E, CabanillasMaria E, DrilonAlexander, EbataKevin, GautschiOliver, GodbertYann, GoldmanJonathan W, HeirichDana, HuangXin, KangHyunseok, KheraniJennifer, KroissMatthias, LakhaniNehal, LaskinJanessa, LeboulleuxSophie, LevyBenjamin, LorchJochen, MedioniJacques, MorenoVictor, MorrisJohn C, NguyenMichele, OwonikokoTaofeek K, PatelJyoti, RobinsonBruce, RothenbergS Michael, ShahManisha H, ShermanEric, SolomonBenjamin, SubbiahVivek, TanDaniel S W, TaylorMatthew H, WeissJared, WirthLori J, WordenFrancis, YangLuxi, ZhuEdward Y, ZhuViola W, de la FouchardièreChristelle

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selpercatinib demonstrated durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer, with or without prior vandetanib or cabozantinib treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: None METHODS: We enrolled patients with RESULTS: In the first 55 consecutively enrolled patients with CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous v...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2005651

データ提供：米国国立医学図書館（NLM）

Selpercatinib: A Hope for RET-Altered Thyroid Cancers

The world of oncology is always looking for new ways to combat the many types of cancer. This study dives into the realm of thyroid cancer, specifically those with alterations in the RET gene. It explores the effectiveness of a targeted therapy called selpercatinib. The researchers used a phase 1-2 clinical trial to test this drug on patients with medullary thyroid cancer, some of whom had previously been treated with other medications. The results are promising, as selpercatinib demonstrated a lasting effect with minimal side effects. This suggests that selpercatinib might be a valuable addition to the treatment options for this type of cancer.

A New Dawn for Medullary Thyroid Cancer Treatment

The study revealed that selpercatinib significantly reduced the size of tumors in patients with RET-altered thyroid cancers. This finding is especially encouraging for those who have previously tried other treatments and haven't found success. Imagine a desert oasis – a source of hope in a vast and challenging landscape. This research offers a potential oasis for patients with this challenging disease.

A Glimpse of Hope in the Desert of Cancer

It's essential to remember that this study is just a step in the journey towards better treatment. More research is needed to confirm these findings and further understand the long-term effects of selpercatinib. While the research indicates a positive outlook, it's important to consult with a medical professional for personalized guidance. This study offers hope that we may be one step closer to conquering this challenging disease.

Dr. Camel's Conclusion

This study, like a camel navigating through a desert, shows that a targeted therapy approach can be effective in treating RET-altered thyroid cancers. Selpercatinib offers a glimmer of hope in this challenging landscape. But like a desert oasis, it's crucial to continue exploring the possibilities and to seek guidance from a medical professional.

Date :
  1. Date Completed 2020-09-14
  2. Date Revised 2021-04-22
Further Info :

Pubmed ID

32846061

DOI: Digital Object Identifier

10.1056/NEJMoa2005651

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.